EN DE
Watch Hyundai Bioscience Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hyundai Bioscience Co. Ltd (048410) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Hyundai Bioscience Co. Ltd stock KRW 3,007, price KRW 5,550, that is 45.8% below the price, quality 19 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7048410005

HB Hyundai Bioscience Co. Ltd logo Thin data Nov 10, 2026

Hyundai Bioscience Co. Ltd

048410 · KQ
Very expensive, weak quality

Our calculation puts a fair price 46% below what the stock costs today.

Low debt
Revenue last quarter +56% vs. a year ago.
Mixed vs. peers (4/7)
Fair value 3,007 KRW · Strongly overvalued
Quality 19/100
Weak Growth (revenue 5y −22.4 %/yr in KRW)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Hyundai Bioscience Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20,000 KRW 4,395 KRW Fair Value 3,007 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 4,395 KRW – 20,000 KRW · fair‑value band 2,255 KRW – 3,759 KRW · the 5,550 KRW price screens above the 3,007 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Hyundai Bioscience Co. in your weekly email

Every Wednesday you see whether Hyundai Bioscience Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin.

Show moreShow less

It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.

Stock analysis

Hyundai Bioscience Co. Ltd (048410) currently trades at 5,550 KRW, while our estimate is 3,007 KRW, 46% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,255 KRW (bear) to 3,759 KRW (bull), the price of 5,550 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Hyundai Bioscience Co. Ltd reported revenue of 3.5B KRW in FY2025 versus 9.2B KRW in FY2021, a compound −21.5%/yr. Reported net income was −22.1B KRW in FY2025.

Key figures

Market cap 533B KRW (≈ $400M) Small · EPS (TTM) −274.01 KRW · Return on equity −24.3% · Return on assets (EBIT) −17.7% (5-year average) · Operating margin −1,064% · Revenue (TTM) 3.3B KRW · Revenue growth (YoY) +56.3% · Free cash flow −37.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −46%, 048410 screens richer than that median.

Fair Value

Bear 2,255 KRW Fair Value 3,007 KRW Bull 3,759 KRW
Price 5,550 KRW · Downside -45.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 19/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 31
How calm the share price moves, does not count
Price momentum 25
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−76.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.4%
Start year 2020 (pandemic). Over 10 years: −21.7% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−58.9% (2020) → −516.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

048410 screens overvalued: fair value 46% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Hyundai Bioscience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside −45.8% · Bottom 25%
Profitability
Return on assets −16.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 56.3% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.81× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 048410
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 048410
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 048410
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 048410
argenx SE ARGX $971.55 $908.40 −7% vs 048410
CSL Limited CSL A$201.68 A$181.40 −10% vs 048410
Moderna, Inc MRNA $250.83 $158.70 −37% vs 048410
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 048410
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 048410
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 048410

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hyundai Bioscience Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hyundai Bioscience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/048410

Frequently asked questions

Is Hyundai Bioscience Co. Ltd (048410) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 3,007 KRW versus a price of 5,550 KRW, about 46% lower (overvalued).
What is the fair value of 048410?
Our estimate for Hyundai Bioscience Co. Ltd is 3,007 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 5,550 KRW.
What is the quality score of 048410?
Hyundai Bioscience Co. Ltd has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyundai Bioscience Co. Ltd (048410)?
Our calculated price target is the estimate of 3,007 KRW (as of Nov 10, 2026). Cautious scenario 2,255 KRW, optimistic scenario 3,759 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Hyundai Bioscience Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 3,007 KRW, about 46% lower versus a price of 5,550 KRW (overvalued). Cautious scenario 2,255 KRW, optimistic scenario 3,759 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Hyundai Bioscience Co. Ltd (048410)?
Hyundai Bioscience Co. Ltd reported trailing-twelve-month revenue of about 3.3B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Hyundai Bioscience Co. Ltd (048410)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyundai Bioscience Co. Ltd it is 3,007 KRW per share (as of Nov 10, 2026), against a price of 5,550 KRW.
Is Hyundai Bioscience Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 048410 trades above its calculated fair value: price 5,550 KRW, fair value 3,007 KRW, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 048410?
No. The price is what the market pays today (5,550 KRW); the fair value is what the company's own numbers justify (3,007 KRW). For Hyundai Bioscience Co. Ltd the two are 2,543 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyundai Bioscience Co. Ltd worth?
The market values Hyundai Bioscience Co. Ltd at about 533B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 5,550 KRW; our models calculate a fair value of 3,007 KRW per share.
What do the bullish and bearish scenarios say about 048410?
Our models span a range for Hyundai Bioscience Co. Ltd: cautious scenario 2,255 KRW, base 3,007 KRW, optimistic 3,759 KRW per share (as of Nov 10, 2026, price 5,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hyundai Bioscience Co. Ltd (048410)?
Balance-sheet figures for Hyundai Bioscience Co. Ltd (as of Nov 10, 2026): return on equity −24.3%. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is 048410 from its 52-week high?
Hyundai Bioscience Co. Ltd trades at 5,550 KRW, about 72% below its 52-week high of 20,000 KRW and 21% above the low of 4,595 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 3,007 KRW is for.
Which stocks are comparable to Hyundai Bioscience Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyundai Bioscience Co. Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 5,550 KRW, calculated fair value 3,007 KRW (−46%), Quality Score 19/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Hyundai Bioscience Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyundai Bioscience Co. Ltd (048410)?
The closing price on Nov 10, 2026 was 5,550 KRW. Our estimate is 3,007 KRW, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyundai Bioscience Co. Ltd right now?
The price sits above even our optimistic bull case (3,759 KRW). The favourable scenario is already priced in. Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Hyundai Bioscience Co. Ltd

How large is the market capitalisation of Hyundai Bioscience Co. Ltd (048410)?
The market capitalisation of Hyundai Bioscience Co. Ltd is 533B KRW (≈ $400M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Hyundai Bioscience Co. Ltd (048410)?
Earnings per share at Hyundai Bioscience Co. Ltd are −274.01 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Hyundai Bioscience Co. Ltd (048410)?
The return on equity (ROE) of Hyundai Bioscience Co. Ltd is −24.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyundai Bioscience Co. Ltd (048410)?
On an EBIT basis the return on assets of Hyundai Bioscience Co. Ltd is −17.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyundai Bioscience Co. Ltd (048410)?
The operating margin of Hyundai Bioscience Co. Ltd is −1,064% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyundai Bioscience Co. Ltd (048410)?
Revenue at Hyundai Bioscience Co. Ltd is growing +56.3% versus a year earlier (3y avg −23.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyundai Bioscience Co. Ltd (048410) generate?
The free cash flow of Hyundai Bioscience Co. Ltd is −37.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hyundai Bioscience Co. Ltd (048410) carry?
The net debt of Hyundai Bioscience Co. Ltd is 22.2B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hyundai Bioscience Co. Ltd in the live analysis

One click puts Hyundai Bioscience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.